Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia

被引：0
|
作者：
Sophie Pöchlauer
Eva Jäger
Ulrich Jäger
Klaus Geissler
机构：
[1] Medical University of Vienna,Department of Laboratory Medicine
[2] Medical University of Vienna,Department of Internal Medicine I, Division of Hematology and Hemostaseology
[3] Ludwig Boltzmann Institute for Clinical Oncology,5th Department of Internal Medicine–Oncology/Hematology
[4] Krankenhaus Hietzing,undefined
来源：
Annals of Hematology | 2014年 / 93卷
关键词：
Myelofibrosis; Ruxolitinib; Chronic Myelomonocytic Leukemia; Exogenous Growth Factor; Clear Drop;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1775 / 1776
页数：1
相关论文
共 50 条
  • [1] Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia
    Poechlauer, S.
    Jaeger, E.
    Jaeger, U.
    Geissler, K.
    ONKOLOGIE, 2013, 36 : 241 - 241
  • [2] Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia
    Poechlauer, Sophie
    Jaeger, Eva
    Jaeger, Ulrich
    Geissler, Klaus
    ANNALS OF HEMATOLOGY, 2014, 93 (10) : 1775 - 1776
  • [3] Inhibitory effect of interleukin-10 on the autonomous in vitro growth of chronic myelomonocytic leukemia cells.
    Geissler, K
    Ohler, L
    Reiter, E
    Kabrna, E
    Rogy, M
    Fodinger, M
    Mannhalter, C
    Jager, U
    Lechner, K
    BLOOD, 1995, 86 (10) : 2645 - 2645
  • [4] Interleukin-10 inhibits growth and GM-CSF expression in chronic myelomonocytic leukemia cells.
    Geissler, K
    Oehler, L
    Fodinger, M
    Reiter, E
    Kabrna, E
    Kollars, M
    Skoupy, S
    Rogy, M
    Mannhalter, C
    Lechner, K
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 576 - 576
  • [5] Interleukin-6 and interleukin-10 gene polymorphisms at chronic lymphoid leukemia patients
    Fistik, S.
    Ozaslan, M.
    Oguzkan, S. Bayil
    Kizikli, A.
    Kilic, I.
    Yilmaz, M.
    LEUKEMIA RESEARCH, 2018, 73 : S33 - S33
  • [6] Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10
    Elaine Radwanski
    Abhijit Chakraborty
    Scott Van Wart
    Richard D. Huhn
    David L. Cutler
    Melton B. Affrime
    William J. Jusko
    Pharmaceutical Research, 1998, 15 : 1895 - 1901
  • [7] Preclinical safety evaluation of recombinant human interleukin-10
    Rosenblum, LY
    Johnson, RC
    Schmahai, TJ
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2002, 35 (01) : 56 - 71
  • [8] Pharmacokinetics and leukocyte responses of recombinant human interleukin-10
    Radwanski, E
    Chakraborty, A
    Van Wart, S
    Huhn, RD
    Cutler, DL
    Affrime, MB
    Jusko, WJ
    PHARMACEUTICAL RESEARCH, 1998, 15 (12) : 1895 - 1901
  • [9] CHARACTERIZATION OF RECOMBINANT EXTRACELLULAR DOMAIN OF HUMAN INTERLEUKIN-10 RECEPTOR
    TAN, JC
    BRAUN, S
    RONG, H
    DIGIACOMO, R
    DOLPHIN, E
    BALDWIN, S
    NARULA, SK
    ZAVODNY, PJ
    CHOU, CC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (21) : 12906 - 12911
  • [10] Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers
    Huhn, RD
    Radwanski, E
    Gallo, J
    Affrime, MB
    Sabo, R
    Gonyo, G
    Monge, A
    Cutler, DL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (02) : 171 - 180
12345